Article Text

other Versions

PDF
Triamcinolone during pars plana vitrectomy for open globe trauma: a pilot randomised controlled clinical trial
  1. Philip J Banerjee1,2,
  2. Wen Xing1,2,
  3. Catey Bunce1,2,
  4. Malcolm Woodcock3,
  5. Aman Chandra1,2,
  6. Robert A H Scott4,
  7. David G Charteris1,2
  1. 1Moorfields Eye Hospital, London, UK
  2. 2NIHR Clinical Research Facility at Moorfields Eye Hospital, London, UK
  3. 3Royal Air force and Worcestershire Acute Hospitals NHS Trust, Worcester, UK
  4. 4Birmingham and Midland Eye Centre, Birmingham, UK
  1. Correspondence to Dr Philip J Banerjee, Vitreoretinal Service, Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; philip.banerjee{at}moorfields.nhs.uk

Abstract

Purpose To investigate the feasibility of conducting a randomised controlled trial in patients undergoing pars plana vitrectomy surgery following open globe trauma (OGT). Additionally, to investigate the treatment effect and toxicity of intensive anti-inflammatory agents.

Methods A 2-year, pilot, single-centre prospective, participant and surgeon-masked randomised controlled trial (RCT). Forty patients requiring vitrectomy surgery following OGT were randomised to either standard (control) or study treatment (adjuncts) in a 1:1 allocation ratio. Perioperatively, the adjunct group received intravitreal and subtenons triamcinolone acetonide, oral flurbiprofen and guttae prednisolone acetate 1%. The control group received standard care. Primary outcome was anatomical success at 6 months. Secondary outcomes included final visual acuity, occurrence of proliferative vitreoretinopathy, intraocular pressure rise, number of operations and recruitment rate.

Results 40 patients were recruited within 21 months. Primary outcome assessment showed similar results in anatomical success with 50% (10/20) in the adjunct group compared with 47% (9/19) in the standard group (OR 1.11, 95% CI 0.316 to 3.904). Visual outcomes were better in the adjunct group with a final median visual acuity of 31 Early Treatment Diabetic Retinopathy Study (ETDRS) letters compared with 25 ETDRS letters in the standard group. A higher proportion of patients gained 10, 20 and 30 ETDRS letters in the adjunct group (80%, 65% and 50%, respectively) compared with the standard group (52.6%, 52.6% and 42.1%). Fewer adjunct patients (15%, n=3) had poor visual outcomes (Zero ETDRS letters) compared with 42.1%, (n=8).

Conclusions An RCT in this population is deliverable and estimated recruitment rates are realistic. Results and patient discussions determined that the definitive study should have vision as a primary outcome. This pilot study is supportive of there being a positive treatment effect of intensive anti-inflammatory agents in OGT.

Trial registration number European Clinical Trials Database 2007-005138-35; Results.

  • Trauma
  • Eye (Globe)
  • Inflammation
  • Treatment Surgery

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton Jost Jonas James Chodosh